Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDGraft
- Development stage
- Unknown
- Lead developer
- Locate Bio
- Modality
- Recombinant Proteins and Enzymes, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Surgical Implantation
01
Overview
LDGraft is an innovative combination product for spinal fusion that utilizes encapsulated recombinant human bone morphogenetic protein-2 (rhBMP-2) within a biodegradable polymer. This formulation delivers a biomimetic, extended release of rhBMP-2 during spinal fusion procedures, specifically targeting bone defects in anterior lumbar interbody fusion (ALIF). The encapsulation provides dose shielding during the early inflammatory phase and shifts the protein's availability to the repair phase of bone healing, addressing issues seen with conventional surface-bound rhBMP-2 delivery, such as excessive early inflammation. LDGraft is designed to optimize bone growth and fusion at the surgical site. It has received FDA Breakthrough Device designation for ALIF, and is being evaluated in prospective clinical trials. Developed by Locate Bio, it incorporates a proprietary protein encapsulation technology and an osteoconductive scaffold[1][2][3][4][5][7][9].
- Brand names
- LDGraft
- Other names
- LDGraft
02
Targets
BMPR2 (Bone morphogenetic protein receptor type 2)BMPR1B (Bone morphogenetic protein receptor type 1B)BMPR1A (Bone morphogenetic protein receptor type 1A)
Beyond the preview
Go deeper on LDGraft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDGraft.